JMCR Partners
VC Fund
Hong Kong, Hong Kong
JMCR Partners is a venture capital firm based in Shanghai, China and was founded in 2013. The firm seeks to invest in the biotechnology and healthcare sectors. JMCR family office was established in 2013, founded to manage the private assets for founder‘s family and close relations，including 隽华资本 JMCR Capital ® , 隽华国际 JMCR Partners ® and JMRE.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 74%
- Fund size:
- $74M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries JMCR Partners invests in
Stages JMCR Partners invests in
Countries JMCR Partners invests in
Investment Focus
Industry
- Biotechnology 8 (35%)
- Health Care 6 (26%)
- Medical 3 (13%)
- Pharmaceutical 3 (13%)
- Therapeutics 2 (9%)
Stage
- Series A 9 (39%)
- Seed 3 (13%)
- Series B 3 (13%)
- Series C 3 (13%)
- Funding Round 2 (9%)
Country
- United States 10 (43%)
- China 3 (13%)
- Belgium 1 (4%)
- Switzerland 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Clues Therapeutics Inc.
|
Integrate multi-technology target screening and drug discovery to improve innovation development efficiency. | $1.3M / Convertible Note / Jul 20, 2020 | |
Anji Pharmaceuticals
|
Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide. | $12M / Series A / Jul 01, 2020 | |
Diagon, Inc.
|
Technology for generation and transplantation of Human Islet-like organoids. | $5M / Convertible Note / May 18, 2020 | |
|
Proviva Therapeutics, Inc
|
Prodrug design platform for cytokines and other fusion proteins | Seed / Jan 02, 2020 | |
VivaVision Biotech
|
VivaVision Biotech is a clinical-stage R&D biopharmaceutical company. | $9.2M / Series C / Sep 26, 2019 | |
|
Anji Pharmaceuticals
|
Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide. | $14M / Series A / Jun 28, 2019 | |
Riparian Pharmaceuticals
|
Riparian Pharmaceuticals is an early stage biotechnology company employing innovative models of vascular pathophysiology to discover novel therapeutics. The company develops medical therapies designed to treat cardiovascular and inflammatory diseases. The company is based in Boston Massachusetts. | $3M / Series A / Oct 12, 2018 | |
|
Clues Therapeutics Inc.
|
Integrate multi-technology target screening and drug discovery to improve innovation development efficiency. | $800K / Seed / Sep 10, 2018 | |
SQZ Biotech
|
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cellengineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges. | $72M / Series C / Aug 08, 2018 | |
|
Tekeluo Biotech
|
Tekeluo Biotech is a Healthcare company. | $4.5M / Series A / Aug 01, 2018 | |
| See all 23 investments → | |||
Co-Investors
Viva Ventures Biotech Fund
19 deals together
Viva BioInnovator
4 deals together
City Hill Ventures
2 deals together
Ming Bioventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does JMCR Partners invest in?
JMCR Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did JMCR Partners last invest?
The most recent investment recorded for JMCR Partners closed in Jul 2020. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
